239 related articles for article (PubMed ID: 26648136)
1. Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro.
Huang X; Huang S; Guo F; Xu F; Cheng P; Ye Y; Dong Y; Xiang W; Chen A
Mol Med Rep; 2016 Jan; 13(1):613-22. PubMed ID: 26648136
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition.
Patntirapong S; Singhatanadgit W; Chanruangvanit C; Lavanrattanakul K; Satravaha Y
J Oral Pathol Med; 2012 Oct; 41(9):713-20. PubMed ID: 22563819
[TBL] [Abstract][Full Text] [Related]
3. IL-1α induces apoptosis and inhibits the osteoblast differentiation of MC3T3-E1 cells through the JNK and p38 MAPK pathways.
Guo C; Yang XG; Wang F; Ma XY
Int J Mol Med; 2016 Jul; 38(1):319-27. PubMed ID: 27220839
[TBL] [Abstract][Full Text] [Related]
4. Effects of zoledronic acid and geranylgeraniol on the cellular behaviour and gene expression of primary human alveolar osteoblasts.
Zafar S; Coates DE; Cullinan MP; Drummond BK; Milne T; Seymour GJ
Clin Oral Investig; 2016 Nov; 20(8):2023-2035. PubMed ID: 26795621
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
6. Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation.
Guicheux J; Lemonnier J; Ghayor C; Suzuki A; Palmer G; Caverzasio J
J Bone Miner Res; 2003 Nov; 18(11):2060-8. PubMed ID: 14606520
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid suppresses transforming growth factor-β-induced fibrogenesis by human gingival fibroblasts.
Komatsu Y; Ibi M; Chosa N; Kyakumoto S; Kamo M; Shibata T; Sugiyama Y; Ishisaki A
Int J Mol Med; 2016 Jul; 38(1):139-47. PubMed ID: 27176567
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid at subtoxic dose extends osteoblastic stage span of primary human osteoblasts.
Zara S; De Colli M; di Giacomo V; Zizzari VL; Di Nisio C; Di Tore U; Salini V; Gallorini M; Tetè S; Cataldi A
Clin Oral Investig; 2015 Apr; 19(3):601-11. PubMed ID: 25055744
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis repressor with caspase recruitment domain enhances survival and promotes osteogenic differentiation of human osteoblast cells under Zoledronate treatment.
Hu L; Han J; Yang X; Wang Y; Pan H; Xu L
Mol Med Rep; 2016 Oct; 14(4):3535-42. PubMed ID: 27573706
[TBL] [Abstract][Full Text] [Related]
10. Activation of p38 MAPK-regulated Bcl-xL signaling increases survival against zoledronic acid-induced apoptosis in osteoclast precursors.
Tai TW; Su FC; Chen CY; Jou IM; Lin CF
Bone; 2014 Oct; 67():166-74. PubMed ID: 25016096
[TBL] [Abstract][Full Text] [Related]
11. Ginkgolide B enhances the differentiation of preosteoblastic MC3T3-E1 cells through VEGF: Involvement of the p38 MAPK signaling pathway.
Luo J; Zhong Y; Huang S; Li L; Zhang C; Zou X
Mol Med Rep; 2016 Nov; 14(5):4787-4794. PubMed ID: 27748928
[TBL] [Abstract][Full Text] [Related]
12. Myricetin induces human osteoblast differentiation through bone morphogenetic protein-2/p38 mitogen-activated protein kinase pathway.
Hsu YL; Chang JK; Tsai CH; Chien TT; Kuo PL
Biochem Pharmacol; 2007 Feb; 73(4):504-14. PubMed ID: 17113042
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid inhibits human osteoblast activities.
Basso FG; Silveira Turrioni AP; Hebling J; de Souza Costa CA
Gerontology; 2013; 59(6):534-41. PubMed ID: 23867757
[TBL] [Abstract][Full Text] [Related]
14. SP600125 reduces lipopolysaccharide-induced apoptosis and restores the early-stage differentiation of osteoblasts inhibited by LPS through the MAPK pathway in MC3T3-E1 cells.
Guo C; Wang SL; Xu ST; Wang JG; Song GH
Int J Mol Med; 2015 May; 35(5):1427-34. PubMed ID: 25760015
[TBL] [Abstract][Full Text] [Related]
15. Relaxin augments BMP-2-induced osteoblast differentiation and bone formation.
Moon JS; Kim SH; Oh SH; Jeong YW; Kang JH; Park JC; Son HJ; Bae S; Park BI; Kim MS; Koh JT; Ko HM
J Bone Miner Res; 2014 Jul; 29(7):1586-96. PubMed ID: 24643989
[TBL] [Abstract][Full Text] [Related]
16. PRGF exerts a cytoprotective role in zoledronic acid-treated oral cells.
Anitua E; Zalduendo M; Troya M; Orive G
Clin Oral Investig; 2016 Apr; 20(3):513-21. PubMed ID: 26201455
[TBL] [Abstract][Full Text] [Related]
17. Astragaloside II induces osteogenic activities of osteoblasts through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.
Kong XH; Niu YB; Song XM; Zhao DD; Wang J; Wu XL; Zhang R; Mei QB
Int J Mol Med; 2012 Jun; 29(6):1090-8. PubMed ID: 22426655
[TBL] [Abstract][Full Text] [Related]
18. Involvement of bone morphogenetic protein-related pathways in the effect of aucubin on the promotion of osteoblast differentiation in MG63 cells.
Li Y; Hu W; Han G; Lu W; Jia D; Hu M; Wang D
Chem Biol Interact; 2018 Mar; 283():51-58. PubMed ID: 29408431
[TBL] [Abstract][Full Text] [Related]
19. Cytoprotective effects of melatonin on zoledronic acid-treated human osteoblasts.
Camacho-Alonso F; Urrutia-Rodríguez I; Oñate-Cabrerizo D; Oñate-Sánchez RE; Rodríguez-Lozano FJ
J Craniomaxillofac Surg; 2017 Aug; 45(8):1251-1257. PubMed ID: 28552199
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway.
Yamashita M; Otsuka F; Mukai T; Otani H; Inagaki K; Miyoshi T; Goto J; Yamamura M; Makino H
J Endocrinol; 2008 Mar; 196(3):601-13. PubMed ID: 18310456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
